Results 151 to 160 of about 16,213 (203)
Comprehensive drug utilization review in neonates: liposomal amphotericin B
Journal of Pharmacy and Pharmacology, 2018 Objectives This drug utilization evaluation aims to review current evidence on safety and efficacy of using liposomal amphotericin B (LAMB) in newborns with candidiasis, and compare it to the conventional preparation.
Chirlie Silver
exaly +2 more sources
Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis
British Journal of Dermatology, 2005 Existing systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna) braziliensis are unsatisfactory. Liposomal amphotericin B has been used extensively for the treatment of visceral leishmaniasis, but in few cases of CL,
Mahdad Noursadeghi, R N Davidson
exaly +2 more sources
Journal of Chemotherapy, 2005 The distribution of amphotericin B in lung tissue was studied in 18 patients with primary or secondary lung cancer who underwent thoracotomy and pulmonary resection.
G Demartini +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Liposomal amphotericin B, AmBisome
Journal of Infection, 1994The unilamellar liposomal formulation of amphotericin B, AmBisome, is composed of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylglycerol and cholesterol. Early studies of its efficacy in an open design showed that remissions could be induced in candidosis and aspergillosis and that doses of up to 5 mg/kg could be used.
openaire +2 more sources
Guidelines for liposomal amphotericin B
American Journal of Health-System Pharmacy, 2003Jennifer L, Mazzola +2 more
openaire +2 more sources
Desensitisation to liposomal amphotericin B
The Journal of Allergy and Clinical Immunology: In Practice, 2017Bella, Shadur +4 more
openaire +2 more sources